Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...

President Donald Trump shared a screenshot of a Wikipedia page that listed his title as the 'Acting President of Venezuela.' ...

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio's investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has ...

Chum salmon taken into account 19percent of your really worth at the 74.six million and you may around 10percent of your own gather at the 23.5 million ...

When in 1965 the Vietnam War was rapidly escalating, many United States Servicemen considered the country and war an inevitable destination. Sergeant Charles Robert Jenkins was no different. He was ...

The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...

Getting your Trinity Audio player ready... Dear Eric: I am a married man in my early 40s with no kids. My wife does a good job keeping in touch with friends of hers from her childhood and throughout ...

Curi Bio’s ribbon cutting in April 2025 for its new headquarters on Seattle’s waterfront. Elliot Fisher, co-founder and chief business officer, cuts the ribbon with a sword while CEO Nicholas Geisse ...

BioCatch, which reportedly aims to prevent financial crime by recognizing patterns in human behavior, announced an upgrade to its digital fraud- and financial crime-detection platform. BioCatch ...

Gentex Corp. (NASDAQ: GNTX) has acquired Toronto-based BioConnect, a biometric authentication provider whose multi-modal platform serves the security and access control industry. Gentex announced the ...

After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug designer Nabla Bio.